Online inquiry

IVTScrip™ mRNA-Anti-VEGFA, AGN 150998(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1927MR)

This product GTTS-WQ1927MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets VEGFA gene. The antibody can be applied in Age-related macular degeneration (AMD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species synthetic construct
RefSeq NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7422
UniProt ID P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-VEGFA, AGN 150998(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ1927MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15813MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, XmAb14045(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA XmAb14045
GTTS-WQ13535MR IVTScrip™ mRNA-Anti-MCAM, PRX-003(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA PRX-003
GTTS-WQ13861MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, REGN-1979(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-1979
GTTS-WQ12371MR IVTScrip™ mRNA-Anti-SAA1, NEOD-001(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA NEOD-001
GTTS-WQ11962MR IVTScrip™ mRNA-Anti-LTA, MLTA3698A(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MLTA3698A
GTTS-WQ9309MR IVTScrip™ mRNA-Anti-HLA, IMP-321(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA IMP-321
GTTS-WQ662MR IVTScrip™ mRNA-Anti-CD276, 8H9(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 8H9
GTTS-WQ5150MR IVTScrip™ mRNA-Anti-Canlupfam IL31, CAN34D3-65(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CAN34D3-65
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW